VASCEPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VASCEPA (VASCEPA).
Icosapent ethyl is a prodrug that is de-esterified to the active metabolite, eicosapentaenoic acid (EPA). EPA reduces hepatic very low-density lipoprotein (VLDL) triglyceride synthesis and secretion, and increases triglyceride clearance from circulating VLDL particles.
| Metabolism | Icosapent ethyl is hydrolyzed by intestinal lipases to EPA, which is then further metabolized primarily via beta-oxidation. Minor metabolism by CYP450 enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4) and conjugation. |
| Excretion | Primarily hepatic metabolism; <1% excreted unchanged in urine. Fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life: ~89 hours (range 66-120 hours) for icosapent ethyl; steady-state achieved after 4 weeks. |
| Protein binding | >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd/F: 88 L (approx. 1.1 L/kg); indicates distribution primarily in plasma and extracellular fluid. |
| Bioavailability | Oral bioavailability: ~20-30% (as icosapent ethyl) under fed conditions; absorption enhanced with high-fat meals. |
| Onset of Action | Serum triglyceride reduction observed within 2-4 weeks of oral dosing; maximal effect by 6-8 weeks. |
| Duration of Action | Duration of triglyceride-lowering effect persists for up to 2 weeks after discontinuation; clinical effect maintained with continued therapy. |
| Molecular Weight | 430.6 Da (as icosapent ethyl methyl ester; active moiety: ethyl eicosapentaenoate) |
4 grams orally once daily (two 0.5-gram capsules twice daily or one 1-gram capsule twice daily) with or without food.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²); use with caution. |
| Liver impairment | No specific dose adjustment per Child-Pugh classification. Not studied in patients with hepatic impairment; use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no recommended dose. |
| Geriatric use | No specific dose adjustment required. Elderly patients may have age-related renal impairment; monitor renal function as per standard practice. |
| 1st trimester | Limited human data: no evidence of fetal harm in animal studies at doses 5 times human exposure. Use only if clearly needed. |
| 2nd trimester | Same as T1: no known risk, but data insufficient to rule out risk. Consider maternal benefit versus potential fetal risk. |
| 3rd trimester | Same as T1: no known risk in third trimester, but monitor for bleeding risk due to antiplatelet effect of omega-3 fatty acids (theoretical). |
Clinical note
Comprehensive clinical and safety monograph for VASCEPA (VASCEPA).
| Placental transfer | Omega-3 fatty acids cross the placenta; specific data for icosapent ethyl not available, but likely to cross similarly to other long-chain fatty acids. |
| Breastfeeding | Excreted in breast milk in small amounts; no adverse effects reported in infants. Caution with high doses due to theoretical risk of bleeding. Consider benefit of breastfeeding outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to icosapent ethyl or any component of the formulationSevere liver impairment (e.g., decompensated cirrhosis)
| Precautions | Increased risk of atrial fibrillation or atrial flutter, particularly in patients with prior cardiac arrhythmias or cardiovascular risk factors, Increased risk of bleeding in patients taking anticoagulants or antiplatelet agents; monitor for signs of bleeding, Potential hypersensitivity reactions including anaphylaxis and angioedema, Elevated liver function tests; monitor periodically, May cause diarrhea, nausea, abdominal pain, Contains ethyl esters; avoid in patients with known hypersensitivity to fish or shellfish |
| Food/Dietary | Take Vascepa with food to enhance absorption. There are no specific dietary restrictions, but patients should adhere to a low-fat diet as recommended for hypertriglyceridemia. Avoid high-fat meals that may interfere with absorption if taken without food. No known interactions with grapefruit or other specific foods. |
Loading safety data…
| Lactation Rating | L2 (Possibly Compatible) |
| Teratogenic Risk | VASCEPA (icosapent ethyl) is classified as FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, no evidence of fetal harm at doses up to 4 times the human systemic exposure. However, because animal reproduction studies are not always predictive of human response, use during pregnancy only if clearly needed. First trimester: No known specific risk. Second and third trimesters: No known adverse effects, but no human data available. |
| Fetal Monitoring | No specific maternal-fetal monitoring required beyond routine prenatal care. Monitor pregnant women for any adverse effects related to the drug, such as bleeding events or arrhythmias, although these are not specifically required. No fetal monitoring indicated. |
| Fertility Effects | No adequate data on the effect of VASCEPA on human fertility. Animal studies did not show impairment of fertility at doses up to 4 times the human systemic exposure. |
| Clinical Pearls | Vascepa (icosapent ethyl) is a high-purity ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes with ≥2 risk factors. It is also indicated to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL). Unlike fish oil supplements, Vascepa is prescription-only and has demonstrated cardiovascular outcome benefits in the REDUCE-IT trial. Avoid use in patients with known hypersensitivity to fish or shellfish. Monitor for atrial fibrillation (more common in patients with history of AF) and bleeding (though risk is low; caution with concurrent anticoagulants). Dose: 2 g twice daily with food. |
| Patient Advice | Take Vascepa exactly as prescribed: 2 capsules (1 gram each) twice daily with food to improve absorption and reduce GI side effects. · Do not switch to over-the-counter fish oil supplements—they are not FDA-approved for these indications and may not provide the same benefits. · You may experience joint pain, muscle pain, or increased liver enzymes; report unusual bleeding or bruising. · Continue your other medications, especially statins, as directed by your doctor. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Do not stop taking Vascepa without consulting your doctor, even if you feel well. · Side effects may include peripheral edema, constipation, and atrial fibrillation; contact your healthcare provider if you experience palpitations or irregular heartbeat. |